Johnson & Johnson

NYSE:JNJ 株式レポート

時価総額：US$653.3b

Johnson & Johnson 将来の成長

Future 基準チェック /06

Johnson & Johnsonの収益は成長。EPSは成長すると14.9%年率で予測されます。

主要情報

n/a

収益成長率

14.90%

EPS成長率

Pharmaceuticals 収益成長18.8%
収益成長率8.1%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日09 Aug 2026

今後の成長に関する最新情報

Recent updates

Seeking Alpha • Aug 15

Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now

Summary Johnson & Johnson has delivered a 28% total return YTD, outperforming SPY and XLV, but now trades at a premium valuation. Despite solid Q2 results and raised FY 2026 guidance, JNJ's stock is deemed fully priced, warranting a reiterated hold rating. Key risks include MedTech growth softness, ongoing litigation, and macro uncertainties, while Pharma momentum drives guidance upgrades. Technically, JNJ remains in an uptrend, but negative RSI divergence and valuation suggest potential near-term consolidation. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 31

JNJ: New Drug Cycle And Talc Settlement Progress Will Balance Policy Risks

Johnson & Johnson's analyst fair value estimate has been raised from $252.87 to $270.59, reflecting higher Street price targets tied to recent Q2 beats, updated guidance, progress on new medicines, and greater clarity around talc litigation exposure. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of enthusiasm around execution on new medicines and MedTech, alongside measured caution on policy and competitive pressures.
ナラティブ更新 • Jul 17

JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026

Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.
ナラティブ更新 • Jul 03

JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules

For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.
分析記事 • Jun 21

Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus

Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...
ナラティブ更新 • Jun 19

JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks

Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.
ナラティブ更新 • Jun 04

JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns

Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.
ナラティブ更新 • May 14

JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns

Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.
ナラティブ更新 • Apr 24

JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks

The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.
ナラティブ更新 • Apr 09

JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience

Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
ナラティブ更新 • Mar 25

JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience

Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
新しいナラティブ • Mar 18

Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability

Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?
ナラティブ更新 • Mar 11

JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty

Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.
ナラティブ更新 • Feb 25

JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk

The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.
ナラティブ更新 • Feb 10

JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance

Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.

業績と収益の成長予測

NYSE:JNJ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028118,944N/A29,98139,8912
12/31/2027108,768N/A27,13134,6944
12/31/2026101,121N/A24,05328,7334
6/28/202697,92921,03721,85927,608N/A
3/29/202696,36221,04017,41322,870N/A
12/28/202594,19326,80419,31324,530N/A
9/28/202592,14925,11919,04824,204N/A
6/29/202590,62722,66116,76623,028N/A
3/30/202589,33121,81018,57424,783N/A
12/29/202488,82114,06618,05924,266N/A
9/29/202487,69614,76719,18725,146N/A
6/30/202486,57616,38219,99524,642N/A
3/31/202485,64817,07218,39623,191N/A
12/31/202385,15913,32617,94022,791N/A
10/1/202383,70312,42115,73720,278N/A
7/2/202382,34812,42214,54719,073N/A
4/2/202377,45810,73016,20720,472N/A
1/1/202379,99016,37017,48821,194N/A
10/2/202284,85517,87917,73921,576N/A
7/3/202288,19717,23619,95023,582N/A
4/3/202294,88019,83019,73323,315N/A
1/2/202278,74017,80119,75823,410N/A
10/3/202191,44617,88022,46126,021N/A
7/4/202189,19017,76722,56426,114N/A
4/4/202184,21415,11520,85324,252N/A
1/3/202182,58414,71420,18923,536N/A
9/27/202080,85616,98618,30721,591N/A
6/28/202080,50315,18517,44320,735N/A
3/29/202082,72917,166N/A23,231N/A
12/29/201982,05915,119N/A23,416N/A
9/29/201981,70614,151N/A23,262N/A
6/30/201981,32516,332N/A22,007N/A
3/31/201981,59314,679N/A22,138N/A
12/30/201881,58115,297N/A22,201N/A
9/30/201881,3821,542N/A22,062N/A
7/1/201880,6841,372N/A22,056N/A
4/1/201878,6931,245N/A21,749N/A
12/31/201776,4501,300N/A21,056N/A
10/1/201774,36115,827N/A21,604N/A
7/2/201772,53116,335N/A20,699N/A
4/2/201772,17416,505N/A19,491N/A
1/1/201771,89016,540N/A18,767N/A
10/2/201671,59515,941N/A17,199N/A
7/3/201670,87715,027N/A17,978N/A
4/3/201670,18215,546N/A18,886N/A
1/3/201670,07415,409N/A19,569N/A
9/27/201570,51714,715N/A18,849N/A

アナリストによる今後の成長予測

収入対貯蓄率: JNJの予測収益成長が 貯蓄率 ( 3.7% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: JNJの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: JNJの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: JNJの収益 ( 8.1% ) US市場 ( 13% ) よりも低い成長が予測されています。

高い収益成長: JNJの収益 ( 8.1% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: JNJの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/19 21:50
終値2026/08/19 00:00
収益2026/06/28
年間収益2025/12/28

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Johnson & Johnson 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53

アナリスト機関
David ToungArgus Research Company
Matthew MiksicBarclays
Lee HambrightBernstein